By a News Reporter-Staff News Editor at Clinical Trials Week -- Neuralstem, Inc. (NYSE MKT: CUR) CEO and President, Richard Garr, will present at the World Stem Cells & Regenerative Medicine Congress, on Thursday, May 22, at 11:35 a.m. BST in London, UK (http://www.terrapinn.com/conference/stem-cells/index.stm). Neuralstem is currently in a Phase II clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) with its NSI-566 stem cells and has been approved to commence a Phase I study in spinal cord injury with the same cells. The company has also completed a Phase Ib trial testing its first-in-class neurogenic compound, NSI-189, in patients with major depressive disorder (MDD) (see also Biotechnology Companies).
GERMANTOWN, Md., May 16, 2014 Mr. Garr's talk is called "Sustainable Growth of Regenerative Medicine: Ensuring Long Term Development and Patient Access to Transformative Cell Therapies." He will also give an update on the clinical programs, including results from the NSI-189 Ib trial.
Keywords for this news article include: Neuralstem Inc., Stem Cell Research, Biotechnology Companies, Clinical Trials and Studies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC